Global Pharmaceutical Contract Development Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma) - Global Forecast to 2027

October 2021 | 236 pages | ID: GDBD340C05B9EN
SPER Market Research

Abstracts

The global pharmaceutical contract development market is expected to grow at a CAGR of ~6.9% from 2020 to reach ~181.0 billion by 2027. The growth is primarily attributed to growing demand for generics and specialty medicines, increasing awareness for biological therapies, rapidly growing investments in R&D & manufacturing technologies by CDMOs, growing nuclear medicine sector and advancing cell & gene therapies. However, lack of skilled professionals and IPR issues are expected to hinder the growth of the market. Increasing need for novel drugs and growth in biologics offer significant growth opportunities for the market players.

By Service: The biologics manufacturing services segment to grow at highest CAGR
Based on services, the pharmaceutical contract development market is segmented into pharmaceutical manufacturing services, drug development services and biologics development services. The biologics manufacturing services is projected to witness highest CAGR during the forecast period. The growth of this segment can mainly be attributed to rapidly increasing demand for vaccines and biologic products. Growing number of biosimilar approvals is further expected to drive the growth of this market.

By End User: Big pharmaceutical companies to dominate the pharmaceutical contract development market
Based on end users, the pharmaceutical contract development market is segmented into big pharmaceutical companies, small & medium sized pharmaceutical companies, generic pharmaceutical companies, and other end users. Big pharmaceutical companies accounted for largest share of the pharmaceutical contract development market, by end user in 2020. The large share is mainly attributed to moving shift towards contract development and manufacturing, increasing demand for end-to-end services, increasing need to regulate costs and pipelining changes.

By Region: North America expected to dominate the regional market
North America is expected to dominate the pharmaceutical contract development market by region. The large share is primarily attributed to large number of clinical trials, presence of leading pharmaceutical companies and large API production base. APAC is expected to register highest CAGR. The growth can be attributed to government initiatives, increasing relevance of off-patent drugs, growing manufacturing sector, skilled professionals in these countries.

Competitive Scenario
Some of the major players are
Thermo Fisher Scientific Inc. (US)
Catalent Inc. (US)
Lonza Group Ltd. (Switzerland)
Recipharm AB (Sweden)
Vetter Pharma International GmbH (Germany)
FAMAR Health Care Services (France)
AbbVie Inc. (US)
Aenova Group (Germany)
Almac Group (UK)
Siegfried Holding AG (Switzerland)
Evonik Industries AG (Germany)
WuXi AppTec (China)
Samsung BioLogics (South Korea)
Boehringer Ingelheim International GmbH (Germany)
Cambrex Corporation (US)
CordenPharma International (Germany)
Albany Molecular Research Inc. (AMRI) (US)
FUJIFILM Corporation (Japan)
Piramal Pharma Solutions (India)
Baxter International Inc. (US)
Eurofins Scientific (Germany)
BioVectra (Canada)
Jubilant Life Science (India)
NextPharma (UK)
Delpharm (France)

Contents

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

4.1. Introduction
4.2. Market Dynamics
  4.2.1. Drivers
  4.2.2. Restraints
  4.2.3. Opportunities
  4.2.4. Challenges
4.3. COVID-19 Impact of the Pharmaceutical Contract Development Market

5. INDUSTRY INSIGHTS

5.1. Introduction
5.2. Industry Trends

6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT MARKET, BY SERVICES, 2019-2027 (USD MILLION)

6.1. Pharmaceutical manufacturing services
6.2. Drug development services
6.3. Biologics manufacturing services

7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT MARKET, BY END USER, 2019-2027 (USD MILLION)

7.1. Big pharmaceutical companies
7.2. Small & medium-sized pharmaceutical companies
7.3. Generic Pharmaceutical Companies
7.4. Other End Users

8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)

8.1. North America
  8.1.1. US
  8.1.2. Canada
8.2. Europe
  8.2.1. Germany
  8.2.2. UK
  8.2.3. France
  8.2.4. Italy
  8.2.5. Spain
  8.2.6. Rest of Europe
8.3. Asia-Pacific
  8.3.1. China
  8.3.2. Japan
  8.3.3. India
  8.3.4. Rest of Asia-Pacific
8.4. Rest of the World
  8.4.1. Latin America
  8.4.2. Middle East & Africa

9. COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Market Share Analysis, By Key Players (2020)
9.3. Competitive Situation and Trends
  9.3.1. Product Launches
  9.3.2. Partnerships, Collaborations and Agreements
  9.3.3. Acquisitions
  9.3.4. Expansions
  9.3.5. Other Developments

10. COMPANY PROFILES

10.1. Thermo Fisher Scientific Inc. (US)
10.2. Catalent, Inc. (US)
10.3. Lonza Group Ltd. (Switzerland)
10.4. Recipharm AB (Sweden)
10.5. Vetter Pharma International GmbH (Germany)
10.6. FAMAR Health Care Services (France)
10.7. AbbVie Inc. (US)
10.8. Aenova Group (Germany)
10.9. Almac Group (UK)
10.10. Siegfried Holding AG (Switzerland)
10.11. Evonik Industries AG (Germany)
10.12. WuXi AppTec (China)
10.13. Samsung BioLogics (South Korea)
10.14. Boehringer Ingelheim International GmbH (Germany)
10.15. Cambrex Corporation (US)
10.16. CordenPharma International (Germany)
10.17. Albany Molecular Research Inc. (AMRI) (US)
10.18. FUJIFILM Corporation (Japan)
10.19. Piramal Pharma Solutions (India)
10.20. Baxter International Inc. (US)
10.21. Eurofins Scientific (Germany)
10.22. BioVectra (Canada)
10.23. Jubilant Life Science (India)
10.24. NextPharma (UK)
10.25. Delpharm (France)

11. APPENDIX